Patient P-02159
Therapy response
Improving
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
76%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 68 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 70 SC-12 recommended — Supportive Compound SC-12
- Day 71 Patient accepted — Started SC-12 in the companion
- Day 76 GI-04 recommended — GI Support Protocol GI-04
- Day 77 Patient accepted — Started GI-04 in the companion
- Day 77 GI symptom burden −12% vs expected — Supportive Compound SC-12
- Day 83 Tolerance state changed — Unstable → Improving
- Day 85 GI symptom burden −35% vs expected — GI Support Protocol GI-04
- Day 91 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 68.
Primary contributors, last 14 days
- Toxicity+12
- Treatment adherence-4
What helped?
- Supportive Compound SC-12Day 70Result: symptom burden −12%
- GI Support Protocol GI-04Day 76Result: symptom burden −35%
LIFE OS recommendation
Monitoring Escalation ME-01
88%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 58
- WearableHRV 18 ms, trending down
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 28/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 62 and rising
- Drug metabolism and exposure ↑20
- BloodToxicity index 50
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 1.9 · butyrate capacity 28/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 19 ms
- Sleep
- 7.0 h
- Steps
- 5,375
- Resting HR
- 69 bpm
Daily log: GI score 62, nutritional resilience 39, adherence 46.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02149 | 57% | S14 | GI-04 | improved | 50 |
| P-02142 | 53% | S14 | GI-04 | improved | 42 |
| P-02185 | 53% | S14 | GI-04 | improved | 51 |
| P-02542 | 50% | S14 | NP-02 | improved | 44 |
| P-02445 | 49% | S09 | GI-04 | improved | 43 |
| P-02125 | 48% | S14 | GI-04 | improved | 55 |
| P-02633 | 47% | S14 | NP-02 | improved | 48 |
| P-02648 | 47% | S14 | SC-12 | improved | 47 |
| P-02643 | 46% | S14 | SC-12 | improved | 46 |
| P-02108 | 45% | S14 | GI-04 | improved | 43 |
| P-02002 | 44% | S14 | GI-04 | improved | 47 |
| P-02118 | 44% | S14 | GI-04 | improved | 47 |